OpenResearchAlpha

Annals of Plastic Surgery · 11 Nov 2026

Factors Associated With Clinical Trial Discontinuation in Aesthetic and Reconstructive Breast Surgery

Tina Moonh-index 0, Bradford Sokol, Tanujit Dey, Andrea Pusic, Erin Taylor

0
Citations
no database records one yet
0
Citations in 2026
so far
0
Leading author's h-index
Tina Moon, in QAI's scholar index
17
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Background: Randomized controlled trials are the gold standard for investigating the safety and efficacy of a new intervention. In particular, clinical trials in aesthetic and reconstructive breast surgery are critical for the advancement of treatment modalities and device development. This study evaluates the factors associated with early discontinuation of breast reconstruction and aesthetic breast surgery-related studies. Methods: A cross-sectional analysis of all breast surgery-related clinical trials on the ClinicalTrials.gov registry was performed. Trials were categorized as aesthetic, reconstructive, or both. Clinical trials related to breast cancer surgery only, without reconstruction, were excluded. Trials listed as “suspended,” “terminated,” or “withdrawn” were defined as discontinued trials. Trials were then further subdivided into 7 study topics, which included: (1) anesthesia/pain management, (2) infection control/wound healing, (3) breast implant/tissue expanders, (4) general breast reconstruction, (5) fat grafting, (6) microsurgery, and (7) patient/surgical education. Additional factors examined included intervention type, funding source, enrollment size, subject gender, subject age, trial start date, and location. Results: A total of 3658 clinical trials were identified with start dates between January 1994 and July 2024. Of these, 565 trials were included in the final analysis. Seventy-eight percent of studies were reconstructive, 8% were aesthetic, and 14% were both. A total of 76 trials were prematurely discontinued, most commonly secondary to low patient accrual (24%), institutional/principal investigator decision (17%), and inadequate staffing (12%). Thirty-nine percent of discontinued trials were device-related, followed by drug/pharmaceutical (33%) and surgical technique (21%). Study category, topic, and study location were not associated with early discontinuation. Observational studies had a significantly lower likelihood of early discontinuation compared with randomized controlled trials [OR=0.23 (0.10-0.48), P <0.001]. Industry-funded studies had a higher likelihood of early discontinuation compared with nonindustry funded studies [OR=2.07 (1.17-3.59), P <0.001]. Conclusion: Successful completion of clinical trials in aesthetic and reconstructive breast surgery is essential for improving patient outcomes. Our study demonstrates that 13.5% of clinical trials did not reach fruition, largely secondary to poor patient recruitment and staffing issues. Targeted efforts to help support trial completion are necessary to help improve evidence-based practice within breast surgery.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Tina Moon has the highest h-index among the authors (0).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (5)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (17)

What it cites, from open citation data, with Crossref's record of each.